PUBLISHER: The Business Research Company | PRODUCT CODE: 1945601
PUBLISHER: The Business Research Company | PRODUCT CODE: 1945601
Metered dose inhalers (MDIs) are medical devices that deliver a specific amount of aerosolized medication directly into the lungs through inhalation. These inhalers are widely used to manage respiratory conditions such as asthma, chronic obstructive pulmonary disease (COPD), and various other lung diseases.
There are several types of metered dose inhaler devices, including desktop metered dose inhalers, portable metered dose inhalers, and others. Desktop metered dose inhalers are fixed devices primarily found in clinical environments, providing a controlled dose of aerosolized medication. These devices are available through both online and offline distribution channels and are commonly used for conditions such as asthma and COPD. They serve a range of end users, including hospitals, clinics, homecare settings, and more.
Tariffs are impacting the metered dose inhaler devices market by increasing costs of imported valves, canisters, and electronic components used in smart inhalers. Portable and smart MDI segments are most affected, particularly in North America and Europe due to reliance on Asia-Pacific manufacturing hubs such as China. These tariffs have raised device pricing and supply costs, but they have also encouraged local manufacturing, innovation in sustainable propellants, and regional sourcing strategies.
The metered dose inhaler devices market research report is one of a series of new reports from The Business Research Company that provides metered dose inhaler devices market statistics, including metered dose inhaler devices industry global market size, regional shares, competitors with a metered dose inhaler devices market share, detailed metered dose inhaler devices market segments, market trends and opportunities, and any further data you may need to thrive in the metered dose inhaler devices industry. This metered dose inhaler devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The metered dose inhaler devices market size has grown strongly in recent years. It will grow from $16.23 billion in 2025 to $17.12 billion in 2026 at a compound annual growth rate (CAGR) of 5.5%. The growth in the historic period can be attributed to rising asthma prevalence, increasing COPD incidence, widespread use of inhalation therapy, physician preference for mdIs, availability of generic inhalers.
The metered dose inhaler devices market size is expected to see strong growth in the next few years. It will grow to $21.06 billion in 2030 at a compound annual growth rate (CAGR) of 5.3%. The growth in the forecast period can be attributed to growth of smart inhalers, environmental regulations on propellants, homecare treatment expansion, digital adherence monitoring demand, emerging respiratory therapies. Major trends in the forecast period include smart dose tracking inhalers, breath-actuated inhalation technology, compact and portable device designs, dose accuracy enhancement, eco-friendly propellant adoption.
The growing prevalence of chronic obstructive pulmonary diseases (COPD) is expected to drive the expansion of the metered dose inhaler (MDI) devices market. COPD is a progressive lung condition marked by airflow restriction, usually caused by prolonged exposure to irritants such as cigarette smoke, and leads to symptoms such as shortness of breath, coughing, and wheezing. The rise in COPD cases can be attributed to factors such as tobacco consumption, air pollution, an aging population, and delayed diagnosis or treatment. MDI devices are vital in managing COPD by delivering medication directly to the lungs, offering rapid relief and improving airflow. For example, in December 2023, the National Institutes of Health, a US-based government agency, projected that COPD cases would increase from 532 million in 2030 to 592 million by 2050. Consequently, the growing prevalence of COPD is fueling the demand for metered dose inhaler devices.
The increasing levels of air pollution are expected to drive the growth of the metered dose inhaler (MDI) devices market in the coming years. Air pollution refers to the presence of harmful substances in the atmosphere, including particulate matter, gases, and biological molecules, which can lead to adverse health effects. Exposure to air pollution is a significant risk factor for respiratory conditions such as asthma and chronic obstructive pulmonary disease (COPD). The rise in air pollution is primarily attributed to industrialization, urbanization, growing vehicular emissions, and the combustion of fossil fuels. MDIs play a vital role in supporting public health by delivering targeted medication to manage respiratory disorders that are triggered or aggravated by polluted air. For example, in October 2025, according to the Clean Air Fund, a UK-based nonprofit philanthropic organization, funding for fossil fuel-related projects increased by 80% in 2023, rising from $5.3 billion to $9.5 billion, contributing to worsening air pollution. Additionally, fossil fuel combustion is responsible for more than 5 million of the 8.1 million premature deaths annually linked to air pollution. Therefore, rising air pollution is fueling the growth of the metered dose inhaler devices market.
Leading companies in the metered dose inhaler devices market are concentrating on developing advanced technologies, such as pressurized metered dose inhalers (pMDIs), to boost medication delivery efficiency and increase patient adherence. pMDIs are devices that release a specific dose of medication in aerosol form using a pressurized propellant. For example, in July 2023, Lupin Limited, an India-based pharmaceutical company, introduced Luforbec 100/6, a pMDI aimed at treating adult asthma and chronic obstructive pulmonary disease (COPD) in Germany. This inhaler combines 100 µg of beclometasone and 6 µg of formoterol, offering an effective combination therapy for patients. Notably, Luforbec is priced around 47% below the fixed reference price, making it more affordable. Given that approximately 5% of adults in Germany suffer from asthma, this launch highlights Lupin's dedication to meeting significant healthcare demands and improving respiratory care outcomes.
Major companies operating in the metered dose inhaler devices market are Pfizer Inc., Merck & Co. Inc., AstraZeneca PLC, GlaxoSmithKline plc, 3M Company, Boehringer Ingelheim GmbH, Teva Pharmaceutical Industries Ltd., Berry Global Inc., AptarGroup Inc., Philips Healthcare, Chiesi Farmaceutici S.p.A., Cipla Limited, Gerresheimer AG, Zydus Lifesciences Limited, Mylan N.V., Nemera, Beximco Pharmaceuticals Limited, Cohero Health Inc., Bespak Europe Ltd., Trudell Medical International, Iconovo AB
North America was the largest region in the metered dose inhaler devices market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the metered dose inhaler devices market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the metered dose inhaler devices market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain
The metered dose inhaler devices market consists of sales of products including bronchodilators, corticosteroids, combination inhalers, and anticholinergics. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Metered Dose Inhaler Devices Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses metered dose inhaler devices market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for metered dose inhaler devices ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The metered dose inhaler devices market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.